Table. Comparison of Pooled Diagnostic Sensitivity and Specificity and Predictive Values for Responders vs Nonresponders After Anti–PD-1/PD-L1 Therapy Between Different Assay Modalitiesa.
| Modality | Pooled Sensitivity | Pooled Specificity | Pooled PPVs | Pooled NPVs |
|---|---|---|---|---|
| PD-L1 IHC (n = 24) | 0.50 (0.48-0.53) | 0.63 (0.62-0.65) | 0.34 (0.32-0.36) | 0.78 (0.76-0.79) |
| TMB (n = 10) | 0.57 (0.51-0.62) | 0.70 (0.66-0.73) | 0.42 (0.38-0.47) | 0.80 (0.77-0.83) |
| GEP (n = 9) | 0.71 (0.67-0.75) | 0.51 (0.48-0.54) | 0.42 (0.39-0.46) | 0.77 (0.74-0.81) |
| mIHC/IF (n = 7) | 0.60 (0.53-0.66) | 0.78 (0.73-0.82) | 0.63 (0.56-0.70) | 0.75 (0.70-0.80) |
| Multimodality (n = 6) | 0.58 (0.50-0.65) | 0.79 (0.75-0.82) | 0.41 (0.33-0.48) | 0.88 (0.85-0.91) |
Abbreviations: GEP, gene expression profiling; mIHC/IF, multiplex immunohistochemistry/immunofluorescence; PD-L1 IHC, programmed cell death ligand 1 immunohistochemistry; TMB, tumor mutational burden.
a
All data are reported as a proportion (95% CI). Nonoverlapping 95% CIs suggest statistical significance.